U.S. markets open in 5 hours 11 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.53+1.12 (+10.76%)
At close: 04:00PM EST
11.53 0.00 (0.00%)
After hours: 07:49PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close10.41
Bid0.00 x 1300
Ask0.00 x 1000
Day's Range10.80 - 11.88
52 Week Range7.70 - 21.59
Avg. Volume1,978,280
Market Cap792.837M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-2.73
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.24
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EDIT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Editas Medicine, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Motley Fool

    Why Editas Medicine Stock Charged Higher in January

    The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.

  • Benzinga

    Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock

    Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ: EDIT) with an Overweight rating and a price target of $15. The analyst says that following the recent pipeline reprioritization and pausing of internal investments in the retinal disease/induced pluripotent stem cell-derived natural killer cell programs, Editas shares are well-positioned to appreciate in the coming year due to favorable IP positioning and expected clinical data updates. Also See: Citing Small Population, Editas

  • InvestorPlace

    7 CRISPR Stocks With the Best Long-Term Potential

    CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks